Brief: Transcenta Says Ind Application Accepted By Nmpa For Pd-L1/Tgf-Β Bi-Functional Antibody Tst005
13/10/2021 16:35
Oct 13 (Reuters) - Transcenta Holding Limited 6628.HK :
* IND APPLICATION ACCEPTED BY NMPA FOR PD-L1/TGF-Β
BI-FUNCTIONAL
ANTIBODY TST005
Source text for Eikon: ID:nHKS8HnXZc
Further company coverage: 6628.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on Transcenta Holding
See all newsBrief: Transcenta Says Global Phase III Trial Of Osemitamab Approved By FDA, China, Korea Regulators
Brief: Transcenta Holding Says Unit To Sell CDMO Assets For RMB190.0 Million
Brief: Transcenta Holding To Revert Assets To Lilly For $4 Million Cash
Brief: Transcenta Therapeutics Appoints Dr. Christopher Hwang As Head Of Global Partnerships For Hicb Platform
Brief: Transcenta Announces Collaboration And Non-Exclusive Licensing Agreement With Eirgenix Inc.